| Literature DB >> 31671654 |
Marta Szyszka1, Lukasz Paschke2, Marianna Tyczewska3, Karol Jopek4, Piotr Celichowski5, Paulina Milecka6, Gulnara Sultanova7, Ewelina Stelcer8,9,10, Agnieszka Malinska11, Ludwik K Malendowicz12, Marcin Rucinski13.
Abstract
Leptin, the first discovered adipokine, has been connected to various physiological and pathophysiological processes, including cancerogenesis. Increasing evidence confirms its influence on prostate cancer cells. However, studies on the effects of leptin on the proliferation and apoptosis of the androgen-sensitive LNCaP line of prostate cancer cells brought conflicting results. Therefore, we performed studies on the effects of high LEP concentration (1 × 10-6 M) on gene expression profile, change of selected signaling pathways, proliferation and apoptosis of LNCaP cells. RTCA (real-time cell analyzer) revealed inhibitory effect of LEP on cell proliferation, but lower LEP concentrations (10-8 and 10-10 M) did not affect cell division. Moreover, flow cytometry with a specific antibody for Cleaved PARP-1, an apoptosis marker, confirmed the activation of apoptosis in leptin-exposed LNCaP line of prostate cancer cells. Within 24 h LEP (10-6 M) increases expression of 297 genes and decreases expression of 119 genes. Differentially expressed genes (DEGs) were subjected to functional annotation and clusterization using the DAVID bioinformatics tools. Most ontological groups are associated with proliferation and apoptosis (seven groups), immune response (six) and extracellular matrix (two). These results were confirmed by the Gene Set Enrichment Analysis (GSEA). The leptin's effect on apoptosis stimulation was also confirmed using Pathview library. These results were also confirmed by qPCR method. The results of Western Blot analysis (exposure to LEP 10 min, 1, 2, 4 and 24 h) suggest (after 24 h) decrease of p38 MAPK, p44-42 mitogen-activated protein kinase and Bcl-2 phosphorylated at threonine 56. Moreover, exposure of LNCaP cells to LEP significantly stimulates the secretion of matrix metallopeptidase 7 (MMP7). Obtained results suggest activation of apoptotic processes in LNCaP cells cultured at high LEP concentration. At the same time, this activation is accompanied by inhibition of proliferation of the tested cells.Entities:
Keywords: LNCaP; apoptosis; intracellular signaling pathways; leptin; proliferation; prostate cancer cells; transcriptome analysis
Mesh:
Substances:
Year: 2019 PMID: 31671654 PMCID: PMC6861914 DOI: 10.3390/ijms20215412
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1(A) Cell index values of LNCaP cells cultivated for 196 h in the presence of various LEP concentrations. Electrical impedance is measured throughout the cultivation period at a 15-minutes frequency. The time point of the medium changed to starvation medium is marked with a blue vertical line. LEP is provided at the time point indicated by a red vertical line. The mean cell index values with SE for the eight repetitions in each group are shown. (B) Flow cytometry analysis of Cleaved PARP-1. Median fluorescence intensity, LNCaP cells treated with LEP (1 × 10−6 M) in relation to untreated control group.
Figure 2(A) Volcano plots of total gene expression profiles of the LNCaP prostate cell line after 24 h incubation with LEP (1 × 10−6 M). Each dot represents the mean expression (n = 2) of the individual gene obtained from a microarray normalized dataset. The orange dotted lines (cut off values) were established according to the following parameters: fold= |2| and p-value with FDR correction = 5%. Genes above the cut-off lines have been considered as differentially expressed genes (DEG) and are shown as turquoise dots. The total numbers of DEG are presented in the bottom right corner of the graph. Ten the most regulated genes are marked by their gene symbols. (B) List of 20 genes with the highest (10 genes) and lowest (10 genes) fold changes obtained from the datasets of differentially expressed genes.
Figure 3Bubble plot of overrepresented gene sets in DAVID GO BP DIRECT annotations database obtained from comparisons in gene expression profiles between LEP-treated LNCaP vs. control. The graph show only the GO groups above the established cut-off criteria (p with correction <0.05, a minimal number of genes per group >10). The size of each bubble reflects the number of differentially expressed genes, assigned to the GO BP terms. Transparency of the bubbles displays p-value (more transparent—closer to the border of p = 0.05).
Figure 4Gene set enrichment analysis using Hallmark gene sets. (A) List of significantly enrichment gene sets with appropriate gene ranks, normalized enrichment score (NES), p values (pval) and p values after FDR correction (padj). (B) Bar chart of normalized enrichment score (NES) values for previously selected gene sets. (C) Enrichment plot of “Hallmark apoptosis” and “Hallmark G2M checkpoint” gene sets.
Figure 5Detailed analysis of five enriched gene ontological groups involved in proliferation/apoptosis. (A) The circular scatter plots of differentially expressed genes involved in specific GO terms (positive regulation of apoptotic process, apoptotic process, regulation of cell proliferation, regulation of apoptotic process, negative regulation of cell proliferation). Each dot represents a single gene whose expression is increased (green) or decreased (red) due to LEP action. Positive value of Z-score mapped on a red colour scale was presented inside the graph. (B) Circos plots with interdependence between selected GO terms and their genes. Symbols of DEG are presented on the left side of the graph with their fold change values, mapped by colour scale (green = higher expression; red = lower expression). Gene involvement in the GO terms was determined by coloured connecting lines.
Figure 6p53 signaling pathway in LNCaP cells treated with LEP (1 × 10−6 M). Expression changes of target genes are mapped by colours; green colour—statistically significant increase in expression, red colour—statistically significant decrease in expression, grey colour—statistically insignificant.
Figure 7Apoptosis pathway in LNCaP cells treated with LEP (1 × 10−6 M). Expression changes of target genes are mapped by colours; green colour—statistically significant increase in expression, red colour—statistically significant decrease in expression, grey colour—expression statistically insignificant.
Figure 8Real time qPCR validation of microarray data. BMX—BMX non-receptor tyrosine kinase, C11orf92—chromosome 11 open reading frame 92, KLK4—kallikrein-related peptidase 4, MYLK—myosin light chain kinase, RIMS1—regulating synaptic membrane exocytosis 1, BIRC3—baculoviral IAP repeat containing, FAS—apoptosis signal receptor/cell surface death receptor, MMP7—matrix metallopeptidase 7, TNFAIP3—tumor necrosis factor, alpha-induced protein 3. Results are presented as means ± SEM, n = 3. Statistical comparison by Student’s t-test: * p < 0.05; ** p < 0.02; *** p < 0.01.
Figure 9Densitometric analysis includes several key factors of signaling pathways involved in apoptosis, proliferation in different time after the treatment with LEP. Graphs represent protein expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. Representative experiments of proteins immunoblotting were also shown. Results are presented as means ± SEM, n = 3. Statistical comparison by Student’s t-test: * p <0.05, ** p<0.01, *** p<0.001.
Figure 10Level of MMP7 in LNCaP cells medium with (blue) or without (red) LEP at 1 × 10−6 M concentration. Levels of MMP7 were measured by ELISA, n = 12 (10−6 M) and n = 13 (control). Results are presented as means ± SEM. Each dot represents an individual sample. Statistical comparison by Student’s t-test: p value shown on the graph.
Figure 11Expression of leptin (LEP), leptin receptor (LEPR) and its main downstream signaling genes (JAK2, STAT3) in normal prostate and adenocarcinoma. Analysis based on data from The Cancer Genome Atlas (TCGA). Results are presented as medians with IQRs. Statistical comparison by Mann-Whitney test: ** p < 0.02; *** p < 0.01.
Literature data on the effect of leptin (LEP) on proliferation and apoptosis in human normal prostate and prostate cancer cell lines.
| Cell Type | Method of Detection | Dose of LEP and Time | Effect | Reference |
|---|---|---|---|---|
| LNCaP-FGC, DU145, PC-3 | [3H]thymidine incorporation | LEP (0.1–12.5 µg/mL) for 20 h | stimulation of proliferation in DU145 and PC-3 cells but not in LNCaP-FGC cell | Onuma et al. (2003) [ |
| DU145 and PC-3 | MTT assay | LEP (0.4 ng/mL and 4.0 ng/mL) for 24 and 48 h | in both cell lines LEP inhibited growth | Somasundar et al. (2003) [ |
| DU145 and PC-3 | MTT assay | LEP (4 or 40 ng/mL) for 24 and 72 h | stimulation of proliferation in both cell lines increased apoptosis in both cell lines | Somasundar et al. (2004) [ |
| DU145 | [3H]thymidine incorporation | LEP (12.5 μg/mL) for 20 h | stimulation of proliferation | Miyazaki et al. (2008) [ |
| LNCaP, DU-145 and PC-3 | [3H]thymidine incorporation | LEP (20–200 ng/mL) for 144h | stimulation of proliferation of LNCaP cells, no effects on PC-3 and Du-145 cells | Deo et al. (2008) [ |
| DU145 and PC-3 | XTT colorimetric assay (tetrazolium based assay) | LEP (5–100 ng/mL) for up to 48 h | stimulation of proliferation in both cell lines anti-apoptotic effects | Hoda & Popken (2008) [ |
| LNCaP and PC3 | CellTiter 96® AQueous One Solution Cell Proliferation Assay (tetrazolium based assay) | LEP (0.01–100 nM) for 48 h | proliferation in LNCaP cells unaffected, in PC3 cells significantly increased | Mistry et al. (2008) [ |
| LNCaP-FGC, DU-145, PC-3, and PC-3 cells stably expressing AR (androgen receptor)—PC-3/AR | apoptosis effector protein caspase 3 levels, cleavage of the DNA repair enzyme, and the numbers of apoptotic cells visualized by Hoechst 33342 | LEP (1 ng/mL) for 24 h | In all studied cell lines statistically significant pro-apoptotic effects of LEP | Samuel-Mendelsohn et al. (2011) [ |
| samples of human hyperplastic prostate tissue | cell proliferation evaluated by immunohistochemistry for PCNA, RT-PCR (expression of apoptosis related genes) | incubation with LEP (50 ng/mL) for 3 h | stimulation of cell proliferation (ca 3-folds) and BAX expression, lowered expression levels of BCL-2 and BCL-X | Leze et al. (2012) [ |
| LNCaP, DU145 and PC-3 | WST-8 assays and a Cell Counting kit-8 | LEP (up to 1000 ng/mL) for 48 h | in all cell lines no effects on cell proliferation, LEP (100 ng/mL) - cell number notably increased between days 7–42 of culture | Noda et al. (2015) [ |
| human normal prostate (PrEC, PrSC, PrSMC) and prostate cancer (DU145, LNCaP, PC3) cell lines | proliferative activity was determined by RTCA (real-time cell analyzer) | LEP (1 × 10−6, 1 × 10−8 and 1 × 10−10 M) for at least 70 h | lowered proliferation rate of LNCaP cells - at 1 × 10−6 M LEP concentration, increased proliferation rate of DU145 cells at the same concentration, increased proliferation rate of PrSC cells at 1 × 10−8 and 1 × 10−10 M LEP concentrations. In all remaining tests LEP did not influence the proliferation rate of the studied cells | Szyszka et al. (2018) [ |
Oligonucleotide sequences of sense (S) and antisense (A) primers.
| Gene Symbol | Genbank Accession Number | Primer | Primer Sequence (5′–3′) | Position | PCR Product Size (bp) |
|---|---|---|---|---|---|
|
| NM_203281.3 | S | CATCGGACACCATCTACCAG | 2053–2072 | 278 |
| BMX non-receptor tyrosine kinase | A | CTTTTGTTTCCTGCCTTGTTC | 2310–2330 | ||
|
| NM_001302644.1 | S | AGCAAGAATATCACCGTGAAGCA | 129–151 | 184 |
| chromosome 11 open reading frame 92 | A | ACCACGATGTCGGGTAACTC | 293–312 | ||
|
| NM_004917.4 | S | CTCTATGACCCGCTGTACCAC | 541–561 | 123 |
| kallikrein-related peptidase 4 | A | CACAAGGCCCTGCAAGTACC | 644–663 | ||
|
| NM_053025.4 | S | AAGTGCTGCTAGATTTGACT | 5781–5800 | 136 |
| myosin light chain kinase | A | AATTAAAGAGCAGTTCCCGTC | 5896–5916 | ||
|
| NM_014989.5 | S | AATATTTCCTGGAGTGCGACTGG | 4830–4852 | 179 |
| regulating synaptic membrane exocytosis 1 | A | GGCTTCGTGCTCTAATGACTT | 4988–5008 | ||
|
| NM_002423.4 | S | ATGATATTAAAGGCATTCAGA | 799–819 | 281 |
| matrix metallopeptidase 7 | A | TTTATTGACATCTACCCACT | 1060–1079 | ||
|
| NM_001270508.1 | S | CCATCATTTTGTACCCTTG | 1132–1150 | 280 |
| TNF alpha induced protein 3 transcript variant 1 | A | TTCAAGTAATCATCTACCAG | 1391–1411 | ||
|
| NM_000043.5 | S | CAAAAGTGTTAATGCCCAA | 378–396 | 299 |
| Fas cell surface death receptor transcript variant 1 | A | TGCAGTTTATTTCCACTTC | 658–676 | ||
|
| NM_001165.4 | S | TAGTAAAAGGAAATATTGCAG | 4294–4314 | 100 |
| baculoviral IAP repeat containing 3 transcript variant 1 | A | TATTTTATGTCCTGTTGCAC | 4374–4393 | ||
|
| NM_000194.2 | S | GCCATCACATTGTAGCCCTC | 343–362 | 172 |
| hypoxanthine phosphoribosyltransferase 1 | A | ACTTTTATGTCCCCTGTTGACT | 493–514 |